Nombre del producto:tert-butyl 3-oxoazetidine-1-carboxylate

IUPAC Name:tert-butyl 3-oxoazetidine-1-carboxylate

CAS:398489-26-4
Fórmula molecular:C8H13NO3
Pureza:95%+
Número de catálogo:CM101906
Peso molecular:171.2

Unidad de embalaje Stock disponible Precio($) Cantidad
CM101906-100g in stock ƿƛ
CM101906-500g in stock ƃǑƃ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :398489-26-4
Fórmula molecular:C8H13NO3
Punto de fusión:-
Código de sonrisas:CC(C)(C)OC(=O)N1CC(=O)C1
Densidad:
Número de catálogo:CM101906
Peso molecular:171.2
Punto de ebullición:
Nº Mdl:MFCD01861741
Almacenamiento:Store at 2-8°C.

Category Infos

Azetidines
Azetidines are an important class of saturated four-membered nitrogen-containing heterocyclic compounds. The research hotspots related to this structure mainly focus on two aspects: one is the research of pharmaceutical chemistry; the other is related to chiral azetidines, using rigid azetidine compounds as chiral ligands for asymmetric catalytic reactions. Many nitrogen-containing heterocycles play important roles in drug structures, and in many cases small structural changes can improve ligand selectivity and pharmacokinetic properties.
Where to buy Azetidines
Where to buy ADC-Cytotoxins? Chemenu Provide Azetidines with high quality and competitive price. Contact us Now.

Column Infos

Alicyclic Heterocycles
When the ends of the chains are joined together into a ring, cyclic compounds result; such substances often are referred to as carbocyclic or alicyclic compounds. Substitution of one or more of the ring carbon atoms in the molecules of a carbocyclic compound with a heteroatom gives a heterocyclic compound.
Emraclidine
Emraclidine is a novel, brain-penetrant, highly selective M4 receptor positive allosteric modulator(PAM) in development for the treatment of schizophrenia.
We believe emraclidine has the potential to provide a significant medical advancement as the muscarinic acetylcholine pathway has long been associated with mediation of neurotransmitter imbalance and psychosis. Emraclidine is the only selective M4 receptor PAM currently in clinical development.